Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE) Karyopharm Therapeutics Announces Oral Presentation at the
- Preclinical efficacy of SINE™ compounds validated in journal Nature publication - - Presentations of ALS abstracts at upcoming AAN and SfN meetings - - Collaborator grant funding supports Karyopharm's ALS research - NEWTON, Mass. , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals — − Karyopharm to Receive $1 Million Upfront Payment, Then Eligible to Receive Up To $43.5 Million in Future Milestones, Plus Royalties — NEWTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) --
-- Antengene Rights Include All Human Oncology Indications for Selinexor, Eltanexor and KPT-9274, and Non-Oncology Human Indications for Verdinexor -- -- Karyopharm to Receive $12 Million (USD) Upfront; Total Deal Valued at up to $162 Million with Karyopharm Eligible to Receive up to $150 Million
- Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS - - Fifth Grant Awarded in Support of KPT-350 as a Potential ALS Treatment Option - NEWTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company,
− ONO Rights Include Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries — − Karyopharm to Receive ¥2.5 billion (US$22.3 Million) Upfront; Total Deal Value up to Approximately US$193.0 million with Karyopharm Eligible to Receive up to ¥19.15
NEWTON, Mass. and PETAH TIKVA , Israel , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group , today announced their entry into an exclusive distribution agreement for the
NEWTON, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnology Index will